<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124524">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02097173</url>
  </required_header>
  <id_info>
    <org_study_id>MC-MTX.12/PK</org_study_id>
    <nct_id>NCT02097173</nct_id>
  </id_info>
  <brief_title>Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen</brief_title>
  <official_title>Relative Bioavailability of Methotrexate (MTX) 50 mg/mL Administered Subcutaneously (SC) by a Disposable Autoinjector (MetojectÂ® Prefilled Pen) Compared With Intramuscular (IM) Administration of the United States Reference Listed Drug Methotrexate Injection (USP 25 mg/mL [Hospira]) in Patients With Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>medac GmbH</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to assess the relative bioavailability of MTX administered
      subcutaneously via a prefilled pen (50mg/mL) compared with MTX administered via IM injection
      (25mg/mL).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>To determine the relative bioavailability of MTX based on the parent compound MTX when administered by SC injection with a prefilled pen (50 mg/mL) as compared with IM administration (25 mg/mL)</measure>
    <time_frame>8 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>SC MTX  followed by IM MTX</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 subcutaneous injection of 30 mg methotrexate administered by a prefilled pen (50mg/mL) followed by 1 intramuscular injection of 30 mg methotrexate (comparator) after a wash-out phase of 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM MTX followed by SC MTX</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 intramuscular injection of 30 mg methotrexate (comparator) followed by 1 subcutaneous injection of 30 mg methotrexate by a prefilled pen (50mg/mL)  after a wash-out phase of 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>SC MTX  followed by IM MTX</arm_group_label>
    <arm_group_label>IM MTX followed by SC MTX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is able to understand and follow instructions during the study

          -  Has a diagnosis of moderate to severe psoriasis based on a dermatologic evaluation

          -  Provides written informed consent

          -  Is male or female and is aged 18 to 65 years, inclusive

          -  Has a body mass index (BMI) within the range 18 through 30 kg/m2.

        Main Exclusion Criteria:

          -  Is receiving concomitant treatment for psoriasis with a biologic or conventional
             systemic treatments (eg, cyclosporine, azathioprine, fumaric acid esters,
             Leflunomide), other than MTX every week

          -  Has used antibiotics within 14 days prior to Screening or requires use prior to study
             completion

          -  Has used any of the following medications within 14 days prior to Screening or
             requires use prior to study completion, unless on a stable, daily dose: Non steroidal
             antiinflammatory drugs (NSAIDs), Diuretics, Folic Acid, Hydrochloroquine, Probenicid,
             Proton-pump inhibitors

          -  Has, other than psoriasis, any uncontrolled cardiac disease, liver disease, lung
             disease, hematologic disease, gastrointestinal disease, or other systemic disease,
             that in the opinion of the investigator, would present an unacceptable risk if he or
             she were to participate in the study

          -  Has ongoing acute or chronic infection within 14 days prior to Screening

          -  Has renal insufficiency , hepatic insufficiency, impaired hematopoiesis, known
             severe, acute, or chronic infection, history of malignancy, history of or suspected
             abuse of drugs or alcohol

          -  allergic reactions or serious adverse reactions to the study drug

          -  Is a female subject who is pregnant, trying to become pregnant, or breast feeding, or
             of childbearing potential, sexually active and not practicing a highly reliable
             method of birth control

          -  Is a male subject with a female partner of childbearing potential, not had a
             vasectomy and not using a condom and/or cervical cap/diaphragm with spermicide
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
